BioSpace News Archive

Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

The Frankfurt Stock Exchange ranks third globally in terms of volume of trading behind the New York Stock Exchange and the Nasdaq Stock Market and will provide BioCure Technology Inc. wider access to European and other international investors.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.

Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended June 30, 2021 and provided a corporate update.

Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on Tuesday, August 10, 2021, at the BofA SMID Cap 2H21 Ideas Conference.

Rigel Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

ChromaDex Corp. announced financial results for the second quarter of 2021.

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m. ET.

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12th Annual Wedbush PacGrow Healthcare Conference